Veru (VERU) Liabilities and Shareholders Equity (2010 - 2026)
Veru (VERU) posted quarterly Liabilities and Shareholders Equity of $43.1 million for Q1 2026, up 31.86% year-over-year from $32.7 million in Q1 2025, and down 9.43% quarter-over-quarter from $47.6 million in Q4 2025.
Veru (VERU) Liabilities and Shareholders Equity (2010 - 2026) Analysis & Trends
Veru (VERU) has reported Liabilities and Shareholders Equity for 17 consecutive years, with $43.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity rose 31.86% year-over-year to $43.1 million; the TTM figure through Mar 2026 stood at $147.8 million (down 25.18% YoY), while the FY2025 annual figure was $29.8 million, down 50.62% from the prior year.
- Liabilities and Shareholders Equity slipped to $43.1 million in Q1 2026 per VERU's latest filing, from $47.6 million in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $172.8 million in Q1 2022 and bottomed at $27.3 million in Q2 2025.
- Historically, Liabilities and Shareholders Equity has averaged $73.4 million across 5 years, with a median of $60.4 million in 2024.
- Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity slumped 63.04% — and 2026, when it jumped 31.86%.
- Veru's Liabilities and Shareholders Equity stood at $101.3 million in 2022, then declined by 20.45% to $80.6 million in 2023, then tumbled by 50.56% to $39.8 million in 2024, then gained by 19.43% to $47.6 million in 2025, then retreated by 9.43% to $43.1 million in 2026.
- Business Quant data shows VERU's Liabilities and Shareholders Equity at $43.1 million in Q1 2026, $47.6 million in Q4 2025, and $29.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Veru | 60.85 Mn | 35.06 Mn | - | 37.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 37.03 Mn |
| Mar 31, 2026 | 43.08 Mn |
| Dec 31, 2025 | 47.57 Mn |
| Sep 30, 2025 | 29.84 Mn |
| Jun 30, 2025 | 27.33 Mn |
| Mar 31, 2025 | 32.67 Mn |
| Dec 31, 2024 | 39.83 Mn |
| Sep 30, 2024 | 60.42 Mn |
| Jun 30, 2024 | 64.63 Mn |
| Mar 31, 2024 | 71.80 Mn |
| Dec 31, 2023 | 80.57 Mn |
| Sep 30, 2023 | 50.02 Mn |
| Jun 30, 2023 | 60.20 Mn |
| Mar 31, 2023 | 70.34 Mn |
| Dec 31, 2022 | 101.27 Mn |
| Sep 30, 2022 | 135.36 Mn |
| Jun 30, 2022 | 160.58 Mn |
| Mar 31, 2022 | 172.83 Mn |
| Dec 31, 2021 | 172.16 Mn |
| Sep 30, 2021 | 178.15 Mn |